Medicure Inc. (MCUJF) Downgraded by Zacks Investment Research

Medicure Inc. (OTCMKTS:MCUJF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Medicure Inc is a cardiovascular drug discovery and development company focused on developing effective therapeutics for unmet needs in the field of cardiovascular medicine. In addition to MC-4232, they are also conducting Phase II clinical trials with MC-1, which is focused on the prevention and treatment of ischemia, ischemic reperfusion injury, and stroke. “

Separately, ValuEngine upgraded Medicure from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th.

Shares of Medicure (MCUJF) opened at 6.26 on Tuesday. Medicure has a 1-year low of $4.11 and a 1-year high of $7.96. The firm has a 50-day moving average price of $6.33 and a 200 day moving average price of $6.21. The company has a market cap of $97.86 million, a PE ratio of 5.81 and a beta of 0.55.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/12/medicure-inc-mcujf-downgraded-by-zacks-investment-research.html.

Medicure Company Profile

Medicure Inc (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS).

Receive News & Ratings for Medicure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply